REGULATORY

Chuikyo OKs NHI Price Listing of SGLT-2 Inhibitors, New Point-Based Calculations Adopted from This Time

May 15, 2014

- Only subscribers can save articles.
  
  Sign In
  
  Subscribe

The Central Social Insurance Medical Council, better known as Chuikyo, approved the reimbursement listing of 14 active pharmaceutical ingredients (APIs)/22 products on May 14, including three sodium-glucose co-transporter-2 (SGLT-2) inhibitors. All these products are slated to join the NHI price…

To read the full story

Chuikyo to Discuss Sharp Difference in NHI Prices of Identical Products Tenozet, Viread
May 16, 2014

REGULATORY

Japan Targets Global-Level Growth for Domestic Patented Drug Market
June 25, 2026
Paxlovid, Awiqli Braced for NHI Price Cuts after CEAs
June 25, 2026
Expert Calls for AMR Ecosystem to Boost Japan Antibiotic Innovation
June 25, 2026
PMDA Eyes AI as Staffing Shortages Affect Orphan Drug Reviews
June 25, 2026
Drug Pricing to Be Applied to Oncolys Oncolytic Virus Therapy
June 25, 2026

Chuikyo Debate on FY2026 Drug Pricing Reform

Chuikyo OKs New CEA Handling, with Third-Party Verification Ahead

Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…

COMMENTARY

Adaptation, Diversification Key as Drug Wholesalers Face Profit Squeeze

By Tatsuya Otsuka

Japan’s leading pharmaceutical wholesalers are bracing for a second consecutive year of profit declines, underscoring the growing challenge of generating…

COLUMN

More Positions, More Candidates: A Snapshot of Movement in Japan’s Pharma Industry

By Philip Carrigan

Recent trends are creating a fascinating push-and-pull effect in the talent market. We’re seeing more positions opening up, but also a greater number of candidates available, particularly in the fields of rare diseases and oncology. This “more positions, more candidates”…